Page last updated: 2024-12-08
ucb 35625
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
UCB 35625: J-113863 is the (trans)-isomer; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 6918496 |
| CHEMBL ID | 277930 |
| CHEMBL ID | 34626 |
| SCHEMBL ID | 8187807 |
| SCHEMBL ID | 8189438 |
| SCHEMBL ID | 8184177 |
| MeSH ID | M0369998 |
Synonyms (38)
| Synonym |
|---|
| j-113863 |
| ucb 35625 |
| j 113863 |
| CHEMBL277930 , |
| chembl34626 |
| 1,4-trans-1-(1-cycloocten-1-ylmethyl)-4-[[(2,7-dichloro-9h-xanthen-9-yl)carbonyl]amino]-1-ethylpiperidinium iodide |
| 353791-85-2 |
| piperidinium, 1-(1-cycloocten-1-ylmethyl)-4-(((2,7-dichloro-9h-xanthen-9-yl)carbonyl)amino)-1-ethyl-, iodide (1:1), trans- |
| HD099HOT7H , |
| j-113863, trans- |
| 342807-82-3 |
| piperidinium, 1-(1-cycloocten-1-ylmethyl)-4-(((2,7-dichloro-9h-xanthen-9-yl)carbonyl)amino)-1-ethyl-, iodide, trans- |
| j-113863, cis- |
| piperidinium, 1-(1-cycloocten-1-ylmethyl)-4-(((2,7-dichloro-9h-xanthen-9-yl)carbonyl)amino)-1-ethyl-, iodide, cis- |
| H942HGF14D , |
| 342807-83-4 |
| piperidinium, 1-(1-cycloocten-1-ylmethyl)-4-(((2,7-dichloro-9h-xanthen-9-yl)carbonyl)amino)-1-ethyl-, iodide (1:1), cis- |
| AKOS025295214 |
| unii-h942hgf14d |
| unii-hd099hot7h |
| 202796-42-7 |
| 202796-41-6 |
| SCHEMBL8187807 |
| SCHEMBL8189438 |
| SCHEMBL8184177 |
| 1,4-cis-1-(1-cycloocten-1-ylmethyl)-4-[[(2,7-dichloro-9h-xanthen-9-yl)carbonyl]amino]-1-ethylpiperidinium iodide |
| J-017805 |
| 301648-08-8 |
| HY-103360 |
| CS-0027742 |
| Q27279862 |
| trans-j-113863 |
| Q27279784 |
| cis-j-113863 |
| 2,7-dichloro-n-[1-[[(1e)-cycloocten-1-yl]methyl]-1-ethylpiperidin-1-ium-4-yl]-9h-xanthene-9-carboxamide;iodide |
| F81765 |
| MS-30985 |
| AKOS040733478 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (8)
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| C-C chemokine receptor type 1 | Homo sapiens (human) | IC50 (µMol) | 0.0101 | 0.0007 | 0.2002 | 2.5000 | AID223365; AID223366; AID43205 |
| Corticotropin-releasing factor receptor 1 | Homo sapiens (human) | IC50 (µMol) | 5.0004 | 0.0007 | 0.0649 | 0.3400 | AID223366; AID223370 |
| C-C chemokine receptor type 2 | Homo sapiens (human) | IC50 (µMol) | 1.0000 | 0.0000 | 0.6736 | 6.6990 | AID223367 |
| C-C chemokine receptor type 1 | Mus musculus (house mouse) | IC50 (µMol) | 0.1569 | 0.0058 | 0.9142 | 5.0000 | AID221354; AID221355; AID221356 |
| C-C chemokine receptor type 3 | Homo sapiens (human) | IC50 (µMol) | 0.0024 | 0.0006 | 0.6041 | 9.0000 | AID223368; AID223369; AID43229 |
| Probable C-C chemokine receptor type 3 | Mus musculus (house mouse) | IC50 (µMol) | 0.4050 | 0.3500 | 0.4050 | 0.4600 | AID221357; AID221358 |
| C-C chemokine receptor type 4 | Homo sapiens (human) | IC50 (µMol) | 10.0000 | 0.2000 | 4.5424 | 10.0000 | AID223370 |
| C-C chemokine receptor type 5 | Homo sapiens (human) | IC50 (µMol) | 1.0000 | 0.0002 | 0.2567 | 9.0000 | AID42494 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (96)
Molecular Functions (18)
Ceullar Components (13)
Bioassays (16)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID223370 | Inhibitory activity against Taer induced increase in intracellular [Ca2+] in KU812 cells expressing human CCR4 receptor | 2001 | Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9 | Design, synthesis, and discovery of a novel CCR1 antagonist. |
| AID43229 | Concentration required for 50% inhibition of [125I]eotaxin binding to human CCR3 receptor expressed in CHO cells | 2001 | Bioorganic & medicinal chemistry letters, May-07, Volume: 11, Issue:9 | Discovery of a novel CCR3 selective antagonist. |
| AID221358 | Inhibitory activity against I-Eotaxin induced [Ca2+] response in mouse CCR3 receptor | 2001 | Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9 | Design, synthesis, and discovery of a novel CCR1 antagonist. |
| AID223367 | Inhibitory activity in human CCR2b receptor | 2001 | Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9 | Design, synthesis, and discovery of a novel CCR1 antagonist. |
| AID221357 | Inhibitory activity against I-Eotaxin alpha binding to mouse CCR3 receptors | 2001 | Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9 | Design, synthesis, and discovery of a novel CCR1 antagonist. |
| AID223373 | Inhibitory activity of Fractalkine-induced increase in [Ca2+] Conc. in HEL cells at human CX3CR1 receptor | 2001 | Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9 | Design, synthesis, and discovery of a novel CCR1 antagonist. |
| AID223365 | Inhibitory activity against [125I]-MIP-1 alpha binding to human CCR1 receptors. | 2001 | Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9 | Design, synthesis, and discovery of a novel CCR1 antagonist. |
| AID223369 | Inhibitory activity against I-Eotaxin induced [Ca2+] response in human CCR3 receptor | 2001 | Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9 | Design, synthesis, and discovery of a novel CCR1 antagonist. |
| AID42494 | Inhibition of RANTES binding to C-C chemokine receptor type 5 | 2001 | Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9 | Design, synthesis, and discovery of a novel CCR1 antagonist. |
| AID223366 | Inhibitory activity against MIP-1 alpha- induced [Ca2+] response in U937 cells expressing human CCR1 receptor | 2001 | Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9 | Design, synthesis, and discovery of a novel CCR1 antagonist. |
| AID221354 | Inhibitory activity against 125 I -MIP-1 alpha binding to mouse CCR1 receptors | 2001 | Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9 | Design, synthesis, and discovery of a novel CCR1 antagonist. |
| AID43205 | Concentration required for 50% inhibition of [125I]eotaxin binding to human CCR1 receptor expressed in CHO cells | 2001 | Bioorganic & medicinal chemistry letters, May-07, Volume: 11, Issue:9 | Discovery of a novel CCR3 selective antagonist. |
| AID221355 | Inhibitory activity against [125I]-MIP-1 alpha binding to mouse CCR1 receptors. | 2001 | Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9 | Design, synthesis, and discovery of a novel CCR1 antagonist. |
| AID221356 | inhibitory activity against MIP-1 alpha- induced [Ca2+] response in U937 cells expressing mouse CCR1 receptor | 2001 | Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9 | Design, synthesis, and discovery of a novel CCR1 antagonist. |
| AID223368 | Inhibitory activity against I-Eotaxin binding to human CCR3 receptors | 2001 | Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9 | Design, synthesis, and discovery of a novel CCR1 antagonist. |
| AID223374 | Inhibitory activity of I-interleukin-8-binding to human neutrophil at human CXCR1,2 receptor | 2001 | Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9 | Design, synthesis, and discovery of a novel CCR1 antagonist. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (13)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (46.15) | 29.6817 |
| 2010's | 6 (46.15) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 13 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||